Carvedilol Beyond the Heart: Pleiotropic Mechanisms and Emerging Therapeutic Applications Across Organ Systems

Area of Science:

• Pharmacology
• Drug Repurposing
• Molecular Biology

Background:

• Carvedilol (CVR) is a nonselective beta-adrenergic antagonist with alpha-1 blocking activity, primarily used for cardiovascular conditions like heart failure and hypertension.
• Emerging evidence indicates Carvedilol possesses diverse pleiotropic effects, including anticancer, neuroprotective, hepatoprotective, renoprotective, cardioprotective, anti-inflammatory, and anti-arthritic activities.

Purpose of the Study:

• To synthesize preclinical and clinical evidence on Carvedilol's non-cardiovascular therapeutic effects.
• To evaluate the molecular mechanisms, translational relevance, and therapeutic potential of Carvedilol beyond its established cardiovascular indications.

Main Methods:

• A comprehensive literature search was performed across major scientific databases (Web of Science, PubMed, Scopus, Google Scholar).
• Included English-language full-text studies reporting preclinical or clinical evidence of Carvedilol's non-cardiovascular effects.
• Synthesized findings from 167 experimental and clinical studies.

Main Results:

• Carvedilol modulates key biological processes including oxidative stress, inflammation, and apoptosis.
• Evidence suggests Carvedilol impacts multiple cell-survival signaling pathways across various organ systems.
• The majority of the evidence supporting these effects is preclinical.

Conclusions:

• Carvedilol demonstrates significant therapeutic potential for non-cardiovascular diseases.
• Its demonstrated pleiotropic effects position Carvedilol as a promising candidate for drug repurposing.
• Further clinical investigation is warranted to validate these preclinical findings and explore Carvedilol's broader therapeutic applications.